Status of aromatase inhibitors in relation to other breast cancer treatment modalities

Endocrine-Related Cancer

Volumn 6, Issue 2, 1999, Pages 277-291

  Ragaz, J ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTIESTROGEN; AROMATASE; AROMATASE INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN RECEPTOR; EXEMESTANE; FADROZOLE; FOLLITROPIN; FORMESTANE; FULVESTRANT; HYDROCORTISONE; LETROZOLE; MEGESTROL ACETATE; PRASTERONE; PYRIDOGLUTETHIMIDE; RALOXIFENE; SP 57050; TAMOXIFEN; TESTOLACTONE; THYROTROPIN; UNCLASSIFIED DRUG; VOROZOLE;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HUMAN; ONCOGENE NEU; ORTHOSTATIC HYPOTENSION; POSTMENOPAUSE; RASH; SOMNOLENCE;

AMINOGLUTETHIMIDE; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; ENZYME INHIBITORS; ESTROGEN ANTAGONISTS; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 0032974115     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0060277     Document Type: Article

References (134)

1. Alexieva-Figusch J, Blankenstein MA, Hop WCJ, Klijn JG, Lamberts SW, de Jong FH, Docter R, Aldercreutz H & van Gilse HA 1984 Treatment of metastatic breast cancer patients with different dosages of megestrol acetate: dose relations, metabolic and endocrine effects. European Journal of Cancer and Clinical Oncology 20 33-40.
2. Beretta KR, Hoefken K, Kvinnsland, S, Trunet P, Chaudri HA, Bhatnagar AS, Goldhirsch A & Cavalli F 1990 CGS 16949A, a new aromatase inhibitor in the treatment of breast cancer: a phase I study. Annals of Oncology 1 421.
3. Bergh J, Bonneterre J, Illiger HJ, Murray R, Nortier J, Paridens R, Rubens RD, Samonigg H & Van Zyl 1997 Vorozole (Rivizor) versus aminoglutethimide (AG) in the treatment of postmenopausal breast cancer relapsing after tamoxifen. Proceedings of the American Society of Clinical Oncology 16 155A.
4. Bhatnagar AS, Hausler A, Schieweck K, Lang M & Bowman R 1990 Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. Journal of Steroid Biochem istry and Molecular Biology 37 1021-1027.
5. Bianco AR, Laurentis MD, Carlomagno C, Lauria R, Petrella G, Pancio L, Pettinato G, Perrone F, Gallo C, Marinelli A et al. 1998 20 year update of the Naples GUN trial of adjuvant breast cancer therapy: evidence of interaction between c-erbB-2 expression and tamoxifen efficacy. Proceedings of the American Society for Clinical Oncology 17 97A.
6. Bilimoria MM, Assikis VJ, Muenzner HD, Wolf DM, Satyaswaroop PG & Jordan VC 1996 An analysis of tamoxifen-stimulated human carcinomas formulations in the AF-2 region of the estrogen receptor. Journal of Steroid Biochemistry and Molecular Biology 58 479-488.
7. th International Congress on Hormonal Steroids, Quebec City, Canada.
8. Bonadonna G, Valagussa P, Brambilla C, Moliterni A, Zambetti M & Ferrari L 1991 Adjuvant and neoadjuvant treatment of breast cancer with chemotherapy and or endocrine therapy. Seminars in Oncology 15 515-524.
9. Bonneterre J, Coppens H, Mauriac L, Metz M, Rouesse J, Armand JP, Fargeot P, Mathieu M, Tubania M & Cappalaere P 1985 Aminoglutethimide in advanced breast cancer: clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/day. European Journal of Cancer and Clinical Oncology 21 1153-1158.
10. Bowler J, Lilley TJ, Pittam JD & Wakeling AE 1989 Novel steroidal pure antiestrogens. Steroids 54 71-79.
11. Breast Cancer Trials Committee 1987 Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet 2 171-175.
12. Brodie AM, Schwarzel WC, Shaikh AA & Brodie HJ 1977 The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3, 17-dione, on estrgen-dependent processes in reproduction and breast cancer. Endocrinology 100 1684-1695.
13. Brodie AM & Nijar VC 1998 Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications. Journal of Steroid Biochemistry and Molecular Biology 66 1-10.
14. Bulun SE, Price TM, Aitken J, Mahendroo MS & Simpson ER 1993 A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. Journal of Clinical Endocrinology and Metabolism 77 1622-1628.
15. Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A et al. 1996 Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. Journal of Clinical Oncology 14 2000-2011.
16. Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P & Webster A 1997 A phase III trial comparing anastrzole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megetrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Cancer 79 730-739.
17. Canetta R, Florentine S, Hunter H & Lenaz L 1983 Megestrol acetate. Cancer Treatment Reviews 10 141-157.
18. Cash R, Brough AJ, Cohen MNP & Satoh PS 1967 Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial. Journal of Clinical Endocrinology 27 1239-1248.
19. Cavalli F, Goldhirsch A, Jungi F, Martz G, Mermillod B & Alberto P 1984 Randomized trial of low-versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer. Journal of Clinical Oncology 2 414-419
20. Clark GM 1998 Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status? Journal of the National Cancer Institute 90 1320-1322.
21. Clemens JA, Bennett DR, Black LJ & Jones CD 1983 Effects of a new antiestrogen keoxifen (LY156758) on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sciences 32 2869-2875.
22. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Paton V, Shak S, Lieberman G & Slamon D 1998 Efficay and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proceedings of the American Society for Clinical Oncology 17 97A.
23. Cole HW, Adrian MD & Shetler PK 1997 Comparative pharmacology of high potency selective estrogen receptor modulators (SERMs): LY353381.HC1 and CP336.156. Journal of Bone and Mineral Research 12 F490.
24. Coombes RC, Hughes SW & Dowsett 1984 4-Hydroxyandrostendione in treatment of postmenopausal patients with advanced breast cancer. Lancet 2 1237-1239.
25. Coombes RC, Hughes SW & Dowsett M 1992 4-Hydroxyandrostendione: a new treatment for postmenopausal patients with breast cancer? European Journal of Cancer 28A 1941-1945.
26. Corkery J, Leonard RCF, Henderson IC, Gelman RS, Hourihan J, Ascoli DM & Salhanick HA 1982 Tamoxifen and aminoglutethimide in advanced breast cancer. Cancer Research 42 3409-3414.
27. CRC Adjuvant Breast Trial Working Party 1988 Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. CRC Adjuvant Breast Trial Working Party. British Journal of Cancer 57 604-607.
28. Cummings SR, Norton L, Eckert S, Grady D, Cauley J, Knickerbocker R, Black DM, Nickelsen T, GLusman J & Krueger K 1998 Raloxifen reduces the risk of breast cancer and may decrease the risk of endometrial cancer in postmenopausal women. Two-year findings form the multiple outcomes of Raloxifen evaluation (MORE) trial. Proceedings of the American Society for Clinical Oncology 17 2A.
29. Cuna GR, Calciati A, Strada MR, Bumma C & Campio L 1978 High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose-response evaluation. Tumori 64 143-149.
30. Cuzick J, Wang DY & Bulbrook RD 1986 The prevention of breast cancer. Lancet 1 83-86.
31. DeFriend DJ, Howell A, Nicholson RI, Anderson E, Dowsett M, Mansel RE, Blarney RW, Bundred NJ, Robertson JF, Saunders C et al. 1994 Investigation of a new pure antiestrogen (ICI 182,780) in women with primary breast cancer. Cancer Research 54 408-414.
32. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M & Christiansen C 1997 Effects of Raloxifen on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. New England Journal of Medicine 337 1641-1647.
33. Diel IJ, Solomyer EF, Costa SD, Gollan C, Goemer R, Wallwiener D, Kaufmann M & Bastert G 1998 Reduction in new metastases in breast cancer with adjuvant clodronate treatment. New England Journal of Medicine 339 357-363.
34. Dixon JM, Love CDB, Tucker S, Bellamy C, Leonard RCF & Miller WR 1998 Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Proceedings of the American Society for Clinical Oncology 17 104A.
35. Dombemowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M et al. 1998 Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. Journal of Clinical Oncology 16 453-461.
36. Dowsett M 1990 Clinical development of aromatase inhibitors for the treatment of breast and prostate cancer. Journal of Steroid Biochemistry and Molecular Biology 37 1037-1041.
37. Dowsett M, Stein RC, Mehta A & Coombes RC 1990 Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients. Clinical Endocrinology 32 623-634.
38. Dowsett M, Lee K, Macaulay VM, Detre S, Rowlands M & Grimsahw R 1996 The control and biological importance of intratumoral aromatase in breast cancer. Journal of Steroid Biochemistry and Molecular Biology 56 145-150.
39. Dowsett M, Daffada A, Chan CM & Johnston SR 1997 Oestrogen receptor mutants and variants in breast cancer. European Journal of Cancer 33 1177-1183.
40. Early Breast Cancer Trialists' Collaborative Group 1992 Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 339 1-15.
41. Early Breast Cancer Trialists' Collaborative Group 1998 Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351 1451-1467.
42. Easton DF, Bishop DT, Ford D & Crockford 1993 Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. American Journal of Human Genetics 52 678-701.
43. Evans TRJ, DiSalle E, Ornti G, Lassus M, Benedetti MS, Pianezzola E & Coombes RC 1992 Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Research 52 5933-5939.
44. Fisher B 1992 Chemoprevention of breast cancer with tamoxifen, the NSABP-B18 trial. Presentation at the National Surgical Adjuvant Breast and Bowel Project Convention.
45. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov NV, Wolmark N, Wickerham DL, Fisher ER et al. 1989 A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. New England Journal of Medicine 320 479-484.
46. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, BVegovic M, DeCillis A, Robidoux A et al. 1998a Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. Journal of Clinical Oncology 16 2672-2685.
47. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J et al. 1998b Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Journal of the National Cancer Institute 90 1371-1388.
48. Fishman LM, Liddle GW, Island DP, Fleischer N & Kuchel O 1967 Effects of aminoglutethimide on adrenal function in man. Journal of Clinical Endocrinology and Metabolism 27 481-490.
49. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Sifversward C, Skoog L, Somell A, Theve T, Wilking N et al. 1989 Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1 117-120.
50. Foster AB, Jarman M, Leung CS, Rowlands MG, Taylor GN, Plevey RG & Sampson P 1985 Analogues of aminoglutethimide: selective inhibition of aromatase. Journal of Medicinal Chemistry 28 200-204.
51. Frei E, Miller D, Clark JR, Fallon BG & Ervin TJ 1986 Clinical and scientific considerations in preoperative (neoadjuvant) chemotherapy. In Preoperative (Neoadjuvant) Chemotherapy, pp 1-6. Eds J Ragaz, J Goldie & P Band. Berlin: Springer-Verlag.
52. Gale KE, Sheehe PR & Gould LV 1976 Treatment of advanced breast cancer with aminoglutethimide: an 8 year experience. Clinical Research 24 376A.
53. Gale KE, Anderson JW, Tormey DC, Mansour EG, Davis TE, Horton J, Wolter JM, Smith TJ & Cummings FJ 1994 Hormonal treatments for metastatic breast cancer. An Eastern Cooperative Oncology Group Phase III trial comparing aminoglutethimide to tamoxifen. Cancer 73 354-361.
54. Gazet JC, Coombes RC, Ford HT, Griffin M, Corbishley C, Makinde V, Lowndes S, Quilliam J & Sutcliffe R 1996 Assessment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer. British Journal of Cancer 73 758-762.
55. Geisler J, King N, Dowsett M, Ottestad L, Lundgren S, Walton P, Kormeset PO & Lonning PE 1996 Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma estrogen levels in postmenopausal women with breast cancer. British Journal of Cancer 74 1286-1291.
56. Goldie JH & Coldman AJ 1979 A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treatment Report 63 1727-1733.
57. Goss PE, Powles TJ, Dowsett M, Hutchison G, Brodie AM, Gazet JC & Coombes RC 1986 Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostendione. Phase II report. Cancer Research 46 4823-4826.
58. Goss PE, Winner EP, Tannock IF & Schwartz LH 1999 Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrole acetate in postmenopausal advanced breast cancer patients. Journal of Clinical Oncology (In Press).
59. Gottardis MM & Jordan VC 1987 Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Research 47 4020-4024.
60. Gottardis MM & Jordan VC 1988 Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Research 48 5183-5187.
61. Griffiths CT, Hall TC, Saba Z, Barlow JJ & Nevinny HB 1973 Preliminary trial of aminoglutethmide in breast cancer. Cancer 32 31-37.
62. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B & King MC 1990 Linkage of early-onset breast cancer to chromosome 17q21. Science 250 1684-1689.
63. Harris AL, Dowsett M, Cantwell BM, Sainsbury JR, Needham G, Farndon J & Wilson R1986 Endocrine effects of low-dose aminoglutethimide with hydrocortisone - an optimal hormone suppressive regimen. Breast Cancer Research and Treatment 7 69-72.
64. Harvey HA, Santen RJ, Osterman J, Samojlik E, White DS & Lipton A 1979 A comparative trial of transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in advanced breast cancer. Cancer 43 2207-2214.
65. Henderson IC 1990 Endocrine therapy of metastatic breast cancer. In Breast Diseases, pp 559-603. Eds J Harris, S Hellman, IC Henderson & DW Kline. Philadelphia: JB Lippincott.
66. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Liprton A, Sinoff C, Wheeler H, Simeone JF, Seaman J & Knight RD 1996 Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. New England Journal of Medicine 335 1785-1791.
67. Howell A, DeFriend D, Robertson J, Blarney R & Walton P 1995 Response to a specific antiestrogen (ICI 182,780) in tamoxifen-resistant breast cancer. Lancet 345 29-30.
68. Hughes SWM & Burley DM 1970 Aminoglutethimide: a 'side effect' turned into therapeutic advantage. Postgraduate Medical Journal 46 409-416.
69. Ingle JN, Green SJ, Ahmann DL, Long HJ, Edmonson JH, Rubin J, Chang MN & Creagan ET 1986 Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. Journal of Clinical Oncology 4 958-964.
70. Johnstone SRD, Smith IE, Doody D, Jacobz S, Robertshaw H & Dowsett M 1994 Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer. Cancer Research 54 5875-5881.
71. Jordan VC 1990 Long-term adjuvant tamoxifen therapy for breast cancer: the prelude to prevention. Cancer Treatment Reviews 17 15-36.
72. Jordan VC 1998 Antiestrogenic action of raloxifen and tamoxifen: today and tomorrow. Journal of the National Cancer Institute 90 967-971.
73. Jordan VC, Glusman JE, Eckert S, Lippman M, Powles T, Costa A, Morrow M & Norton L 1998 Incident primary breast cancers are reduced by raloxifen: integrated data from multicenter, double-blind randomized trials in 12 000 postmenopausal women. Proceedings of the American Society for Clinical Oncology 17 122A.
74. Kopans DB 1997 An overview of the breast cancer screening controversy. Monographs of the National Cancer Institute 22 1-3.
75. Lipton A, Harvey HA, Santen RJ, Boucher A, White D, Bernath A, Dixon R, Richards G & Shafik A 1982 Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer Research 42 3434-3436.
76. Lipton A, Harvey HA, Demers LM, Hanagan JR, Mulagha MT, Kochak GM, Fitzsimmons S, Sanders SI & Santen RJ 1990 A phase I trial of CGS 16949A. A new aromatase inhibitor. Cancer 65 1279-1285.
77. Lonning PE, Jacobs S, Jones A, Haynes B, Powles T & Dowsett M 1991 The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. British Journal of Cancer 63 789-793.
78. Lonning PE, Paridaens R, Thurlimannn B, Piscitelli G & di Salle E 1997 Exemestane experience in breast cancer treatment. Journal of Steroid Biochem is try and Molecular Biology 61 151-155.
79. Love RR 1990 Prospects for antiestrogen chemoprevention of breast cancer. Journal of the National Cancer Institute 82 18-21.
80. Love RR, Mazess RB, Tormey DC, Barden HS, Newcomb PA & Jordan VC 1988 Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Research and Treatment 12 297-302.
81. Love RR, Newcomb PA, Wiebe DA, Surawicz TS, Jordan VC, Carbone PP & DeMets DL 1990 Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. Journal of the National Cancer Institute 82 1327-1332.
82. Lu Q, Nakamura J, Savinov A, Yue W, Weisz J, Dabbs DJ, Wolz G & Brodie A 1996 Expression of aromatase protein and messenger RNA in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers. Endocrinology 137 3061-3068.
83. McDonald CC & Stewart HJ 1991 Fatal myocardial infarction in the Scottish Adjuvant Tamoxifen Trial. The Scottish Breast Cancer Committee. British Medical Journal 303 435-437.
84. McGuire WL, Chamness GC & Fuqua SA 1991 Estrogen receptor variants in clinical breast cancer. Molecular Endocrinology 5 1571-1577.
85. Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, Fernando IN, Ashley SE, Ormerod MG, Titley JC, Gregory RK et al. 1997 Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clinical Cancer Research 3 593-600.
86. Marty M, Gershanovich M, Campos B, Romieu G, Lurie H, Bonaventura T, Jeffery M, Buzzi R, Ludwig H, Bodrogi I et al. 1997 Letrozole, a new potent selective aromatase inhibitor (AI) superior to aminoglutethimide (AG) in postmenopausal women with advanced breast cancer (ABC) previously treated with antiestrogens. Proceedings of the American Society for Clinical Oncology 16 156A.
87. Mauriac L, Durand M, Avril A & Dilhuydy JM 1991 Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Annals of Oncology 2 347-354.
88. Messeih AA, Lipton A, Santen RJ, Harvey HA, Boucher AE, Murray R, Ragaz J, Buzdar AU, Nagel GA & Henderson IC 1985 Aminoglutethimide induced hematologic toxicity: worldwide experience. Cancer Treatment Report 69 1003-1004.
89. Miki JM, Lee MK, Newman B & Skolnick M 1994 Linkage of early onset breast cancer to chromosome 17q21. Science 250 1684.
90. Miller WR & Forrest APM 1974 Oestradiol synthesis by a human breast carcinoma. Lancet 2 866-868.
91. Miller WR, Mullen P, Sourdaine P, Watson C, Dixon JM & Telford J 1997 Regulation of aromatase activity within the breast. Journal of Steroid Biochemistry and Molecular Biology 61 193-202.
92. Muggia FNM, Cassileth PA, Ochoa M Jr, Flatow FA, Gelhorn A & Hyman GA 1968 Treatment of breast cancer with medroxyprogesterone acetate. Annals of Internal Medicine 68 328-337.
93. Muss HB, Wells HB, Paschold EH, Black WR, Cooper MR, Capizzi RL, Christian R, Cruz JM, Jackson DV, Powell BL et al. 1988 Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis - a phase III trial of the Piedmont Oncology Association. Journal of Clinical Oncology 6 1098-1106.
94. Muss HB, Case LD, Capizzi RL, Cooper MR, Cruz J, Jackson D, Richards Fd, Powell BL, Spurr CL, White D et al. 1990 High-versus standard-dose megesterol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association. Journal of Clinical Oncology 8 1797-1805.
95. Osborne CK, Coronado E, Allred DC, Weibe V & DeGregorio M 1991 Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. Journal of the National Cancer Institute 83 1477-1482.
96. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL & Nicholson RI 1995 Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. Journal of the National Cancer Institute 87 746-750.
97. Osborne KC, Clark GM & Ravdin PM 1996 Adjuvant systemic therapy of primary breast cancer. In Disease of the Breast, pp 548-579, Eds JR Harris, ME Lippman, M Morrow & S Hellman. Philadelphia: Lippincott Raven.
98. Overgaard M, Hansen PS, Overgaard J, Rose C, Anderson M, Bach F, Kjaer M, Gadeberg CC, Mouridsen HT, Jensen NB et al. 1997 Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. New England Journal of Medicine 337 949-955.
99. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL & Wolmark N 1998 erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. Journal of the National Cancer Institute 90 1361-1370.
100. Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J & Asjley S 1993 Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. Journal of Clinical Oncology 11 59-65.
101. Plourde V, Dyroff M & Dukes M 1994 Arimidex: a potent and selective fourth generation aromatase inhibitor. Breast Cancer Research and Treatment 30 103-111.
102. Powles T, Ashley S, Ford HT, Gazet JC, Nash AG, Neville AM & Coombes RC 1984 Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially. Lancet 1 1369-1373.
103. Powles TJ, Davey J & Mckinna A 1989a Chemoprevention of breast cancer. Acta Oncologica 28 865-867.
104. Powles TJ, Hardy JR, Ashley SE, Farrington GM, Cosgrove D, Davey JB, Dowsett M, McKinna JA, Nash AG, Sinnett HD et al. 1989b A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. British Journal of Cancer 60 126-131.
105. Powles TJ, Hickish TF, Makris A, Ashley SE, O'Brien ME, Tidy VA, Casey S, Nash AG, Sacks N, Cosgrove D et al. 1995 Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. Journal of Clinical Oncology 13 547-552.
106. Powles TJ, Paterson AHG, Nevantaus A, Legault S, Pajunen M, Tidy VA, Roosenqvist K, Smith IE, Ottestad L, Ashley S et al. 1998 Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer. Proceedings of the American Society for Clinical Oncology 17 123A.
107. Ragaz J 1981 Combination of hormones for metastatic carcinoma of the breast: aminoglutethimide plus tamoxifen in combination versus aminoglutethimide alone versus tamoxifen alone. Reviews on Endocrine-Related Cancer Suppl 547-563.
108. Ragaz J & Coldman A 1998 Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer and thromboembolic episodes. Journal of Clinical Oncology 16 2018-2024.
109. Ragaz J, Buskard N & Manji M 1984 Thrombocytopenia after combination therapy with aminoglutethimde and tamoxifen: which drug is to blame? Cancer Treatment Reports 68 1015-1016.
110. Ragaz J, Olivotto I, O'Reilly S, Kuusk U, Plenderleith IH, Ng V & Basco V 1991 The significance of mastectomy in patients with locally advanced breast cancer treated with preoperative (neoadjuvant) therapy: is there a need for randomization? Proceedings ofthe American Societyfor Clinical Oncology 10 41.
111. Ragaz J, Baird R, Rebbeck P, Trevisan C, Goldie J, Coldman A, Plenderleith IH & Basco V 1997a Preoperative (neoadjuvant) versus postoperative adjuvant chemotherapy for stage I-II breast cancer. Long-term analysis of British Columbia randomized trial. Proceedings of the American Society for Clinical Oncology 16 142A.
112. Ragaz J, Jackson SM, Le N, Plenderleith IH, Spinelli JJ, Basco VE, Wllson KS, Knowling MA, Coppin CM, Paradis M et al. 1997b Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. New England Journal of Medicine 337 956-962.
113. Ravdin PM, Green S, Albain KS, Boucher V, Ingle J, Pritchard K, Shepard L, Davidson N, Hayes DF, Clark GM et al 1998 Inititial report of the SWOG Biological Correlative Study of C-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen alone. Proceedings of the American Society for Clinical Oncology 17 97A.
114. Robertson JFR, Blarney RW, Howell A, Anderson L, DeFriend D & Walton P 1996 Duration of response to ICI 182,780 appears significantly longer than Megace in tamoxifen-resistant breast cancer. Breast Cancer Research and Treatment 37 33.
115. Robustelli Della Cuna G, Calciati A, Strada MRB et al. 1978 High dose medroxyprogesterone acetate treatment of metastatic carcinoma of the breast a dose-response evaluation. Tumori 64 143-149.
116. Rose C, Kamby C, Mouridsen HT, Bastholt L, Brincker H, Skovgaard-Poulsen H, Anderson AP, Loft H, Dombemowsky P & Andersen KW 1986 Combined endocrine treatment of postmenopausal patients with advanced breast cancer: a randomized trial of tamoxifen vs tamoxifen plus aminoglutethimide and hydrocortisone. Breast Cancer Research and Treatment 7 45-50.
117. Rossner S & Wallgren A 1984 Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 52 339-346.
118. Rowley E, Adrian MD & Bryant H 1997 LY353381.HCL, is a new SERM with potent bone and lipid effects without stimulation of uteri. Journal of Bone and Mineral Research 12 F490.
119. Rutqvist LE & Mattsson A 1993 Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. Journal of the National Cancer Institute 85 1398-1406.
120. Samojlik E, Santen RJ & Wells SA 1977 Adrenal suppression with aminoglutethimide II. Differential effects of aminoglutethimide on plasma androstendione and estrogen levels. Journal of Clinical Endocrinology and Metabolism 45 480-487.
121. Santen RJ, Samojlik E, Lipton A, Harvey H, Ruby EB, Wells SA & Kendall J 1977 Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. Cancer 39 2948-2958.
122. Santen RJ, Worgul TJ, Samojlik E, Interrante A, Boucher AE, Lipton A, Harvey HA, White DS, Smart E, Cox C et al. 1981 A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. New England Journal of Medicine 305 545-551.
123. Slamon D, Leyland-Jones B, Shak S, Paton V, Bajamonde A, Fleming T, Eirmann W, Wolter J, Baselga J & Norton L 1998 Addition of herceptin (Humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpresing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized multinational controlled phase III trial. Proceedings of the American Society for Clinical Oncology 17 98A.
124. Smith IE, Harris AL, Morgan M, Gazet JC & McKinna JA 1982 Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. Cancer Research 42 3430-3433.
125. Sporn M, Suh N, Peer C, Williams C, Roebuck B, Glasebrook A, Palkowitz A, Bryant H, Sato M, Yang N et al. 1997 LY353381-HC1, a new benzothiophene for chemoprevention of breast cancer. Proceedings of the American Society for Cancer Research 38 3538.
126. Swift M, Morrel D, Massey RB & Cahse CL 1991 Incidence of cancer in 161 families affected by ataxia-telangiectasia. New England Journal of Medicine 325 1831-1836.
127. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred C et al. 1998 erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. Journal of the National Cancer Institute 90 1346-1360.
128. Thurlinmann B, Paridaens R, Serin D, Bonneterre J, Roche H, Murray R, di Salle E, Lanzalone S, Zurlo MG & Piscitelli G 1997 Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study, Exemestane Study Group. European Journal of Cancer 33 1767-1773.
129. Trunet PF, Mueller PH, Girard F, Aupetit B, Bhatnagar AS, Zognbi F, Ezzet F & Menard J 1992 The effects of fadrozole hydrochloride on aldosterone secretion in healthy male subjects. Journal of Clinical Endocrinology and Metabolism 74 571-576.
130. Trunet PF, Bhatnagar AS, Chaudri HA & Hornberger 1996 Letrozole (CGS 20267), a new oral aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal patients. Acta Oncologica 35 15-18.
131. Turken S, Siris E, Seldin D, Flaster E, Hyman G & Lindsay R 1989 Effects of tamoxifen on spinal bone density in women with breast cancer. Journal of the National Cancer Institute 81 1086-1088.
132. Upright C, Ragaz J, Basco V & Grafton 1990 Double blind randomized trial of conventional versus low-dose aminoglutethimide and hydrocortisone in patients with metastatic hormone responsive breast cancer. Proceedings of the American Society for Clinical Oncology 9 A170.
133. Van Landegham AA, Portman J, Nabauurs M & Thijssen JH 1985 Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Research 45 2900-2906.
134. Weber BL & Garber JE 1996 Familial breast cancer. In Diseases of the Breast, pp 168-185. Eds JR Harris, ME Lippman, M Morrow & S Helman. Philadelphia: Lippincot Raven.